Geographic MismatchNCT07890181
Geographic Mismatch as A Predictor of Short-Term Major Adverse Cardiovascular Events Following Long Coronary Stent Implantation
An observational study of Geographic Mismatch and Short-Term, run by Sohag University at 1 site in Egypt.
Trial summary
This study aims to evaluate whether geographic mismatch is an independent predictor of short-term major adverse cardiovascular events following long coronary stent implantation. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Geographic Mismatch, Short-Term, Major Adverse Cardiovascular Events
- What is being tested?
- Coronary Stent Implantation
- Type of treatment
- Surgery or procedure
- How many people
- 650 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2026to 1 May 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: This prospective multi-center observational cohort study will be conducted in the Cardiology Department on 650 patients.
Who may be able to join
- Age ≥18 years old.
- Both sexes.
- Patients undergo percutaneous coronary intervention (PCI) with successful implantation of a drug-eluting stent (DES) measuring ≥38 mm in length.
- Successful stent deployment with discharge after PCI.
Who cannot join
- Bare-metal stent (BMS) implantation.
- Cardiogenic shock at presentation.
- In-stent restenosis lesions.
- Previous stent implantation in the target coronary segment.
- Life expectancy <6 months due to non-cardiac causes.
- Incomplete clinical or geographic data.
- Patients lost to follow-up immediately after hospital discharge.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Egypt1 site, 1 recruiting
- Recruiting
Sohag University
Sohag, 82511
Remon S Adly, MD, 00201221878986, remonsaleh@yahoo.com
About this study
Official title: Geographic Mismatch as A Predictor of Short-Term Major Adverse Cardiovascular Events Following Long Coronary Stent Implantation; A Prospective Cohort Study
This study aims to evaluate whether geographic mismatch is an independent predictor of short-term major adverse cardiovascular events following long coronary stent implantation.
Read the detailed description
Coronary artery disease (CAD) remains one of the leading causes of morbidity and mortality worldwide despite substantial advances in preventive strategies, pharmacological therapy, and coronary revascularization techniques.
Percutaneous coronary intervention (PCI) has become the standard treatment for many patients with obstructive CAD and has significantly improved both short- and long-term clinical outcomes.
Several clinical, angiographic, and procedural factors have been identified as predictors of adverse outcomes following PCI, including advanced age, diabetes mellitus, chronic kidney disease, left ventricular dysfunction, lesion complexity, and total stent length.
- Conditions
- Geographic Mismatch, Short-Term, Major Adverse Cardiovascular Events, Long Coronary Stent Implantation
- Being tested
- Coronary Stent Implantation
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Coronary Stent ImplantationProcedure or surgery
Patients undergo percutaneous coronary intervention (PCI) with successful implantation of a drug-eluting stent (DES) measuring ≥38 mm in length
| Study group | Role | What they receive |
|---|---|---|
| Geographic mismatch group | Patients with geographic mismatch. Receives: Procedure: Coronary Stent Implantation | |
| Non-geographic mismatch group | Patients without geographic mismatch. Receives: Procedure: Coronary Stent Implantation |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of Major Adverse Cardiovascular Events
Incidence of Major Adverse Cardiovascular Events (MACE) will be recorded within 30 days post-percutaneous coronary intervention (PCI).
Measured: 30 days post-percutaneous coronary intervention
Secondary outcomes (6)
Incidence of all-cause mortality
Incidence of all-cause mortality will be recorded within 60 days.
Measured: 60 days post-percutaneous coronary intervention
Occurrence of myocardial infarction
Number of participants who experience myocardial infarction following the index percutaneous coronary intervention (PCI).
Measured: 30 days post-percutaneous coronary intervention
Occurrence of target lesion revascularization
umber of participants who undergo repeat revascularization of the target lesion following the index percutaneous coronary intervention (PCI).
Measured: 30 days post-percutaneous coronary intervention
Occurrence of definite stent thrombosis
Number of participants who experience definite or probable thrombosis of the stent implanted during the index percutaneous coronary intervention (PCI).
Measured: 30 days post-percutaneous coronary intervention
Hospital readmission
Number of participants who are readmitted to a hospital following discharge from the index percutaneous coronary intervention (PCI) hospitalization.
Measured: 30 days post-percutaneous coronary intervention
Length of index hospital stay
Duration of the index hospitalization during which percutaneous coronary intervention (PCI) is performed, measured in days.
Measured: 60 days post-percutaneous coronary intervention
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted22 Oct 2026
- Study start1 Sep 2026
- Primary completion1 May 2027 (estimated)
- Study completion1 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Geographic MismatchStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 650 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Remon Saleh Adly, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07890181
- Sponsor's protocol ID
- 20260930017
- Status last verified
- Oct 2026
- First submitted
- 18 Oct 2026
- Last updated
- 22 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Study at a glance
From the registry record, last updated by the sponsor on 22 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Geographic Mismatch as A Predictor of Short-Term Major Adverse Cardiovascular Events Following Long Coronary Stent Implantation; A Prospective Cohort Study
- ClinicalTrials.gov ID
- NCT07890181
- Acronym / sponsor ID
- 20260930017
- Conditions
- Geographic Mismatch, Short-Term, Major Adverse Cardiovascular Events, Long Coronary Stent Implantation
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 650 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- 1 Sep 2026 (actual)
- Primary completion
- 1 May 2027 (estimated)
- Study completion
- 1 May 2027 (estimated)
- First posted
- 22 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study aims to evaluate whether geographic mismatch is an independent predictor of short-term major adverse cardiovascular events following long coronary stent implantation.
Detailed description
Coronary artery disease (CAD) remains one of the leading causes of morbidity and mortality worldwide despite substantial advances in preventive strategies, pharmacological therapy, and coronary revascularization techniques.
Percutaneous coronary intervention (PCI) has become the standard treatment for many patients with obstructive CAD and has significantly improved both short- and long-term clinical outcomes.
Several clinical, angiographic, and procedural factors have been identified as predictors of adverse outcomes following PCI, including advanced age, diabetes mellitus, chronic kidney disease, left ventricular dysfunction, lesion complexity, and total stent length.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Geographic mismatch group | – | Procedure: Coronary Stent ImplantationPatients with geographic mismatch. |
| Non-geographic mismatch group | – | Procedure: Coronary Stent ImplantationPatients without geographic mismatch. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- This prospective multi-center observational cohort study will be conducted in the Cardiology Department on 650 patients.
Key inclusion criteria (4 listed)
- Age ≥18 years old.
- Both sexes.
- Patients undergo percutaneous coronary intervention (PCI) with successful implantation of a drug-eluting stent (DES) measuring ≥38 mm in length.
- Successful stent deployment with discharge after PCI.
Key exclusion criteria (7 listed)
- Bare-metal stent (BMS) implantation.
- Cardiogenic shock at presentation.
- In-stent restenosis lesions.
- Previous stent implantation in the target coronary segment.
- Life expectancy <6 months due to non-cardiac causes.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Coronary Stent ImplantationPatients undergo percutaneous coronary intervention (PCI) with successful implantation of a drug-eluting stent (DES) measuring ≥38 mm in length | Procedure or surgery | Geographic mismatch group, Non-geographic mismatch group |
Primary outcome
Incidence of Major Adverse Cardiovascular Events
Time frame: 30 days post-percutaneous coronary intervention
Incidence of Major Adverse Cardiovascular Events (MACE) will be recorded within 30 days post-percutaneous coronary intervention (PCI).
6 secondary outcomes
Incidence of all-cause mortality
Time frame: 60 days post-percutaneous coronary intervention
Occurrence of myocardial infarction
Time frame: 30 days post-percutaneous coronary intervention
Occurrence of target lesion revascularization
Time frame: 30 days post-percutaneous coronary intervention
Occurrence of definite stent thrombosis
Time frame: 30 days post-percutaneous coronary intervention
Hospital readmission
Time frame: 30 days post-percutaneous coronary intervention
Length of index hospital stay
Time frame: 60 days post-percutaneous coronary intervention
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Oct 2026.
- Individual participant dataSharing planned: Yes. The data will be available upon a reasonable request from the corresponding author after the end of study for one year.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Geographic Mismatch and Short-Term, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 22 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Remon S Adly, MD (00201221878986, remonsaleh@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of Major Adverse Cardiovascular Events (time frame: 30 days post-percutaneous coronary intervention). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Oct 2026.